This study is an access and distribution protocol for unlicensed cryopreserved cord blood
units (CBUs) in pediatric and adult patients with hematologic malignancies and other
indications.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT01351545 .
State: All California Connecticut Georgia Illinois Iowa Maryland Massachusetts Michigan Missouri Nebraska New Jersey New York North Carolina Ohio Oklahoma Oregon Pennsylvania South Carolina Tennessee Texas Utah Virginia Washington Wisconsin
Locations matching your search criteria
United States California Duarte City of Hope Comprehensive Cancer Center Status: Active
Name Not Available
Los Angeles UCLA / Jonsson Comprehensive Cancer Center Status: Active
Contact: Gary John Schiller
Phone: 310-206-5755
Children's Hospital Los Angeles Status: Active
Name Not Available
San Diego UC San Diego Medical Center - Hillcrest Status: Active
Contact: Edward D. Ball
Phone: 858-822-6600
San Francisco UCSF Medical Center-Mission Bay Status: Active
Contact: UCSF Clinical Trials
Phone: 877-827-3222
University of California San Francisco Status: Active
Contact: UCSF Clinical Trials
Phone: 877-827-3222
Connecticut New Haven Yale University Status: Active
Name Not Available
Georgia Atlanta Emory University Hospital/Winship Cancer Institute Status: Active
Contact: Edmund Kemp Waller
Children's Healthcare of Atlanta - Arthur M Blank Hospital Status: Active
Name Not Available
Illinois Chicago University of Chicago Comprehensive Cancer Center Status: Active
Contact: James Laurence LaBelle
Phone: 773-702-6812
Lurie Children's Hospital-Chicago Status: Active
Contact: Sonali Chaudhury
Phone: 312-227-4863
Iowa Iowa City University of Iowa/Holden Comprehensive Cancer Center Status: Active
Name Not Available
Maryland Baltimore Johns Hopkins University/Sidney Kimmel Cancer Center Status: Active
Contact: Allen R. Chen
Massachusetts Boston Dana-Farber Cancer Institute Status: Active
Contact: Corey S. Cutler
Brigham and Women's Hospital Status: Active
Name Not Available
Boston Children's Hospital Status: Active
Name Not Available
Beth Israel Deaconess Medical Center Status: Temporarily closed to accrual
Name Not Available
Michigan Ann Arbor University of Michigan Rogel Cancer Center Status: Active
Name Not Available
Detroit Wayne State University/Karmanos Cancer Institute Status: Active
Contact: Voravit Ratanatharathorn
Missouri Saint Louis Siteman Cancer Center at Washington University Status: Active
Contact: Peter Westervelt
Phone: 800-600-3606
Nebraska Omaha University of Nebraska Medical Center Status: Active
Contact: Phyllis Irene Warkentin
Phone: 402-559-6941
New Jersey New Brunswick Rutgers Cancer Institute of New Jersey Status: Active
Contact: Matthew J Matasar
New York Buffalo Roswell Park Cancer Institute Status: Active
Name Not Available
New York Icahn School of Medicine at Mount Sinai Status: Active
Contact: Amir S. Steinberg
Memorial Sloan Kettering Cancer Center Status: Active
Contact: Juliet Naomi Barker
Phone: 212-639-7202
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center Status: Active
Contact: Monica Bhatia
Laura and Isaac Perlmutter Cancer Center at NYU Langone Status: Active
Name Not Available
Rochester University of Rochester Status: Active
Name Not Available
North Carolina Chapel Hill UNC Lineberger Comprehensive Cancer Center Status: Active
Name Not Available
Charlotte Carolinas Medical Center/Levine Cancer Institute Status: Active
Name Not Available
Durham Duke University Medical Center Status: Active
Contact: Joanne Kurtzberg
Ohio Cleveland Case Comprehensive Cancer Center Status: Active
Contact: Brenda Wimpfheimer Cooper
Phone: 216-844-3951
Columbus Nationwide Children's Hospital Status: Active
Name Not Available
Ohio State University Comprehensive Cancer Center Status: Active
Name Not Available
Oklahoma Oklahoma City University of Oklahoma Health Sciences Center Status: Active
Name Not Available
Oregon Portland OHSU Knight Cancer Institute Status: Active
Contact: Eneida R. Nemecek
Pennsylvania Philadelphia University of Pennsylvania/Abramson Cancer Center Status: Active
Name Not Available
Pittsburgh University of Pittsburgh Cancer Institute (UPCI) Status: Active
Name Not Available
South Carolina Charleston Medical University of South Carolina Status: Active
Contact: Michelle Phillips Hudspeth
Phone: 843-792-0381
Tennessee Memphis Saint Jude Children's Research Hospital Status: Active
Contact: Renee M. Madden
Nashville Vanderbilt University/Ingram Cancer Center Status: Active
Contact: Adetola A. Kassim
Phone: 615-936-1803
Texas Dallas UT Southwestern/Simmons Cancer Center-Dallas Status: Active
Name Not Available
Houston M D Anderson Cancer Center Status: Active
Contact: Elizabeth Joan Shpall
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center Status: Active
Name Not Available
Texas Children's Hospital Status: Active
Name Not Available
Utah Salt Lake City Huntsman Cancer Institute/University of Utah Status: Active
Name Not Available
Primary Children's Hospital Status: Active
Name Not Available
Virginia Charlottesville University of Virginia Cancer Center Status: Active
Name Not Available
Richmond VCU Massey Comprehensive Cancer Center Status: Active
Contact: John Michael McCarty
Phone: 804-828-4596
Washington Seattle Fred Hutch/University of Washington/Seattle Children's Cancer Consortium Status: Active
Name Not Available
Wisconsin Madison University of Wisconsin Carbone Cancer Center - University Hospital Status: Active
Contact: Mark B. Juckett
Phone: 608-265-4363
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center Status: Active
Contact: Mark B. Juckett
Principal Investigators:
The principal investigators (PIs) will be transplant physicians at all participating U.S.
transplant centers.
Study Design:
This study is an access and distribution protocol for unlicensed cryopreserved cord blood
units (CBUs) in pediatric and adult patients with hematologic malignancies and other
indications.
Primary Objective:
The primary objective of this study is to examine the incidence of neutrophil recovery of
≥500/mm3 after cord blood transplantation in a multi-institution setting using CBUs that
are not Food and Drug Administration (FDA) licensed.
Secondary Objectives:
In patients receiving a non-licensed CBU:
- Assess incidence of transmission of infection
- Assess incidence of serious infusion reaction
- Determine 1 year overall survival after cord blood transplantation
- Assess cumulative incidence of acute graft vs. host disease (GVHD) grades II to IV
and grades III to IV
- Assess cumulative incidence of chronic GVHD
- Determine platelet engraftment of >20,000 mcL and >50,000 mcL
Trial Phase No phase specified
Trial Type Not provided by clinicaltrials.gov
Lead Organization Center for International Blood and Marrow Transplant Research
